Department of Neurology (T. Yoshimoto, M.I.), National Cerebral and Cardiovascular Center, Suita, Japan.
Department of Clinical Neuroscience and Therapeutics, Hiroshima University, Japan (T. Yoshimoto).
Stroke. 2022 Aug;53(8):2549-2558. doi: 10.1161/STROKEAHA.121.038285. Epub 2022 Apr 20.
We determined the long-term event incidence among elderly patients with nonvalvular atrial fibrillation in terms of history of stroke/transient ischemic attack (TIA) and oral anticoagulation.
Patients aged ≥75 years with documented nonvalvular atrial fibrillation enrolled in the prospective, multicenter, observational All Nippon Atrial Fibrillation in the Elderly Registry between October 2016 and January 2018 were divided into 2 groups according to history of stroke/TIA. The primary end point was the occurrence of stroke/systemic embolism within 2 years, and secondary end points were major bleeding and all-cause death within 2 years. Cox models were used to determine whether there was a difference in the hazard of each end point in patients with/without history of stroke/TIA, and in ischemic stroke/TIA survivors taking direct oral anticoagulants versus those taking warfarin.
Of 32 275 evaluable patients (13 793 women [42.7%]; median age, 81.0 years), 7304 (22.6%) had a history of stroke/TIA. The patients with previous stroke/TIA were more likely to be male and older and had higher hazard rates of stroke/systemic embolism (adjusted hazard ratio, 2.25 [95% CI, 1.97-2.58]), major bleeding (1.25, 1.05-1.49), and all-cause death (1.13, 1.02-1.24) than the other groups. Of 6446 patients with prior ischemic stroke/TIA, 4393 (68.2%) were taking direct oral anticoagulants and 1668 (25.9%) were taking warfarin at enrollment. The risk of stroke/systemic embolism was comparable between these 2 groups (adjusted hazard ratio, 0.90 [95% CI, 0.71-1.14]), while the risk of major bleeding (0.67, 0.48-0.94), intracranial hemorrhage (0.57, 0.39-0.85), and cardiovascular death (0.71, 0.51-0.99) was lower among those taking direct oral anticoagulants.
Patients aged ≥75 years with nonvalvular atrial fibrillation and previous stroke/TIA more commonly had subsequent ischemic and hemorrhagic events than those without previous stroke/TIA. Among patients with previous ischemic stroke/TIA, the risk of hemorrhagic events was lower in patients taking direct oral anticoagulants compared with warfarin.
URL: https://www.
gov; Unique Identifier: UMIN000024006.
我们根据中风/短暂性脑缺血发作(TIA)病史和口服抗凝治疗,确定了老年非瓣膜性心房颤动患者的长期事件发生率。
2016 年 10 月至 2018 年 1 月期间,在前瞻性、多中心、观察性的全日本老年心房颤动注册研究中,纳入了年龄≥75 岁、有记录的非瓣膜性心房颤动患者,并根据中风/TIA 病史将其分为 2 组。主要终点是 2 年内发生中风/系统性栓塞,次要终点是 2 年内主要出血和全因死亡。Cox 模型用于确定有/无中风/TIA 病史的患者在每个终点的风险是否存在差异,以及缺血性中风/TIA 幸存者服用直接口服抗凝剂与服用华法林的风险是否存在差异。
在 32275 例可评估患者中(13793 例女性[42.7%];中位年龄 81.0 岁),7304 例(22.6%)有中风/TIA 病史。与其他组相比,有既往中风/TIA 的患者更可能为男性和年龄更大,且中风/系统性栓塞(调整后的危险比,2.25[95%CI,1.97-2.58])、主要出血(1.25,1.05-1.49)和全因死亡(1.13,1.02-1.24)的风险更高。在 6446 例既往有缺血性中风/TIA 的患者中,4393 例(68.2%)正在服用直接口服抗凝剂,1668 例(25.9%)正在服用华法林。这两组之间的中风/系统性栓塞风险相当(调整后的危险比,0.90[95%CI,0.71-1.14]),而主要出血(0.67,0.48-0.94)、颅内出血(0.57,0.39-0.85)和心血管死亡(0.71,0.51-0.99)的风险较低。
年龄≥75 岁的非瓣膜性心房颤动且有既往中风/TIA 的患者比无既往中风/TIA 的患者更常发生随后的缺血性和出血性事件。在既往有缺血性中风/TIA 的患者中,与华法林相比,服用直接口服抗凝剂的患者出血事件的风险较低。
gov;独特标识符:UMIN000024006。